Literature DB >> 8656664

Myocardial adenylyl cyclase type V and VI mRNA: differential regulation with age.

P J Scarpace1, M Matheny, N Tümer.   

Abstract

Myocardial beta-adrenergic signal transduction diminishes with age. This decrease is not due to a decrease in the number of beta-adrenoceptors, but may be a result of an impaired capacity to activate adenylyl cyclase (AC). Forskolin-stimulated AC activity is diminished, and the number of forskolin binding sites is decreased, suggesting that the decrease in signal transduction with age is a result of fewer AC catalytic units. To investigate whether the decrease in AC with age is associated with diminished AC mRNA, we assessed AC type V and type VI mRNA in ventricles from 6-, 11-, and 24-month-old F-344 rats. The predominant mRNA species, type V, increased by 45% between 6 and 11 months of age but decreased to just below the 6-month level by age 24 months. In contrast, type VI mRNA decreased by 44% between 6 and 11 months of age and then increased to the 6-month level at age 24 months. The changes in type V and type VI mRNA did not parallel the decreases in the AC activity or forskolin binding sites with senescence. These data indicate that the steady-state levels of type V and VI AC mRNA are not reliable predictors of the efficacy of forskolin stimulation of AC activity at different ages.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656664     DOI: 10.1097/00005344-199601000-00014

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload.

Authors:  Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

Review 2.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  Adenylyl cyclase type 5 protein expression during cardiac development and stress.

Authors:  Che-Lin Hu; Rachna Chandra; Hui Ge; Jayashree Pain; Lin Yan; Gopal Babu; Christophe Depre; Kousaku Iwatsubo; Yoshihiro Ishikawa; Junichi Sadoshima; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-04       Impact factor: 4.733

Review 4.  Pathological cardiac hypertrophy: the synergy of adenylyl cyclases inhibition in cardiac and immune cells during chronic catecholamine stress.

Authors:  Gabriel Komla Adzika; Jeremiah Ong'achwa Machuki; Wenkang Shang; Hongjian Hou; Tongtong Ma; Lijuan Wu; Juan Geng; Xide Hu; Xianluo Ma; Hong Sun
Journal:  J Mol Med (Berl)       Date:  2019-05-06       Impact factor: 4.599

Review 5.  Function of Adenylyl Cyclase in Heart: the AKAP Connection.

Authors:  Tanya A Baldwin; Carmen W Dessauer
Journal:  J Cardiovasc Dev Dis       Date:  2018-01-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.